1. Fanciulli A, Wenning GK. Multiple-system atrophy. N Engl J Med. 2015;372:249–63.
2. Koga S, Dickson DW. Recent advances in neuropathology, biomarkers and therapeutic approach of multiple system atrophy. J Neurol Neurosurg Psychiatry. 2018;89:175–84.
3. Trojanowski JQ, Revesz T, Neuropathology Working Group on MSA. Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol. 2007;33:615–20.
4. Yoshida M. Multiple system atrophy: alpha-synuclein and neuronal degeneration. Neuropathology. 2007;27:484–93.
5. Ozawa T, Paviour D, Quinn NP, Josephs KA, Sangha H, Kilford L, et al. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain. 2004;127:2657–71.
6. Wenning GK, Stefanova N, Jellinger KA, Poewe W, Schlossmacher MG. Multiple system atrophy: a primary oligodendrogliopathy. Ann Neurol. 2008;64:239–46.
7. Cykowski MD, Coon EA, Powell SZ, Jenkins SM, Benarroch EE, Low PA, et al. Expanding the spectrum of neuronal pathology in multiple system atrophy. Brain. 2015;138:2293–309.
8. Jellinger KA. Multiple system atrophy: an oligodendroglioneural synucleinopathy. J Alzheimers Dis. 2018;62:1141–79.
9. Aoki N, Boyer PJ, Lund C, Lin WL, Koga S, Ross OA, et al. Atypical multiple system atrophy is a new subtype of frontotemporal lobar degeneration: frontotemporal lobar degeneration associated with alpha-synuclein. Acta Neuropathol. 2015;130:93–105.
10. Homma T, Mochizuki Y, Komori T, Isozaki E. Frequent globular neuronal cytoplasmic inclusions in the medial temporal region as a possible characteristic feature in multiple system atrophy with dementia. Neuropathology. 2016;36:421–31.
11. Horoupian DS, Dickson DW. Striatonigral degeneration, olivopontocerebellar atrophy and “atypical” Pick disease. Acta Neuropathol. 1991;81:287–95.
12. Piao YS, Hayashi S, Hasegawa M, Wakabayashi K, Yamada M, Yoshimoto M, et al. Co-localization of alpha-synuclein and phosphorylated tan in neuronal and glial cytoplasmic inclusions in a patient with multiple system atrophy of long duration. Acta Neuropathol. 2001;101:285–93.
13. Rohan Z, Rahimi J, Weis S, Kapas I, Auff E, Mitrovic N, et al. Screening for alpha-synuclein immunoreactive neuronal inclusions in the hippocampus allows identification of atypical MSA (FTLD-synuclein). Acta Neuropathol. 2015;130:299–301.
14. Saito M, Hara M, Ebashi M, Morita A, Okada K, Homma T, et al. Perirhinal accumulation of neuronal alpha-synuclein in a multiple system atrophy patient with dementia. Neuropathology. 2017;37:431–40.
15. Shibuya K, Nagatomo H, Iwabuchi K, Inoue M, Yagishita S, Itoh Y. Asymmetrical temporal lobe atrophy with massive neuronal inclusions in multiple system atrophy. J Neurol Sci. 2006;179:50–8.
16. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71:670–6.
17. Ideno Y, Takayama M, Hayashi K, Takagi H, Sugai Y. Evaluation of a Japanese version of the Mini-Mental State Examination in elderly persons. Geriatr Gerontol Int. 2012;12:310–6.
18. Jeong JW, Kim KW, Lee DY, Lee SB, Park JH, Choi EA, et al. A normative study of the Revised Hasegawa Dementia Scale: comparison of demographic influences between the Revised Hasegawa Dementia Scale and the Mini-Mental Status Examination. Dement Geriatr Cogn Disord. 2007;24:288–93.
19. Riku Y, Watanabe H, Mimuro M, Iwasaki Y, Ito M, Katsuno M, et al. Non-motor multiple system atrophy associated with sudden death: pathological observations of autonomic nuclei. J Neurol. 2017;264:2249–57.
20. Jellinger KA, Seppi K, Wenning GK. Grading of neuropathology in multiple system atrophy: proposal for a novel scale. Mov Disord. 2005;20:S29–36.
21. Lee YH, Ando T, Lee JJ, Baek MS, Lyoo CH, Kim SJ, et al. Later-onset multiple system atrophy: a multicenter Asian study. Mov Disord. 2020;35:1692–3.
22. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389–404.
23. Thal DR, Rub U, Orantes M, Braak H. Phases of A betadeposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791–800.
24. Saito Y, Ruberu NN, Sawabe M, Arai T, Tanaka N, Kakuta Y, et al. Staging of argyrophilic grains: an age-associated tauopathy. J Neuropathol Expe Neurol. 2004;63:911–8.
25. Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142:1503–27.
26. Mitsui J, Matsukawa T, Ishiura H, Fukuda Y, Ichikawa Y, Date H, et al. Mutations in COQ2 in familial and sporadic multiplesystem atrophy. N Engl J Med. 2013;369:233–44.
27. Mitsui J, Matsukawa T, Sasaki H, Yabe I, Matsushima M, Dürr A, et al. Variants associated with Gaucher disease in multiple system atrophy. Ann Clin Transl Neurol. 2015;2:417–26.
28. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.
29. Arima K, Murayama S, Mukoyama M, Inose T. Immunocytochemical and ultrastructural studies of neuronal and oligodendroglial cytoplasmic inclusions in multiple system atrophy. 1. Neuronal cytoplasmic inclusions. Acta Neuropathol. 1992;83:453–60.
30. Uchihara T, Nakamura A, Mochizuki Y, Hayashi M, Orimo S, Isozaki E, et al. Silver stainings distinguish Lewy bodies and glial cytoplasmic inclusions: comparison between Gallyas-Braak and Campbell-Switzer methods. Acta Neuropathol. 2005;110:255–60.
31. Koga S, Li F, Zhao N, Roemer SF, Ferman TJ, Wernick AI, et al. Clinicopathologic and genetic features of multiple system atrophy with Lewy body disease. Brain Pathol. 2020;30:766–78.
32. Watanabe H, Saito Y, Terao S, Ando T, Kachi T, Mukai E, et al. Progression and prognosis in multiple system atrophy—an analysis of 230 Japanese patients. Brain. 2002;125:1070–83.
33. Wenning GK, Tison F, BenShlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord. 1997;12:133–47.
34. Koga S, Parks A, Uitti RJ, van Gerpen JA, Cheshire WP, Wszolek ZK, et al. Profile of cognitive impairment and underlying pathology in multiple system atrophy. Mov Disord. 2017;32:405–13.
35. Miki Y, Foti SC, Hansen D, Strand KM, Asi YT, Tsushima E, et al. Hippocampal alpha-synuclein pathology correlates with memory impairment in multiple system atrophy. Brain. 2020;143:1798–810.
36. Lantos PL. The definition of multiple system atrophy: a review of recent developments. J Neuropathol Exp Neurol. 1998;57:1099–111.
37. Yazawa I, Giasson BI, Sasaki R, Zhang B, Joyce S, Uryu K, et al. Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron. 2005;45:847–59.
38. Nishie M, Mori F, Yoshimoto M, Takahashi H, Wakabayashi K. A quantitative investigation of neuronal cytoplasmic and intranuclear inclusions in the pontine and inferior olivary nuclei in multiple system atrophy. Neuropathol Appl Neurobiol. 2004;30:546–54.